Phase i and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 6, 2009, Pages 1073-1082

  Xu, Y ^a   Kolesar, J M ^b   Schaaf, L J ^c   Drengler, R ^d   Duan, W ^a   Otterson, G ^a   Shapiro, C ^a   Kuhn, J ^d   Villalona Calero, M A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d San Antonio Cancer Institute   (United States)

Author keywords

Celecoxib; Irinotecan; Mitomycin C; Modulation; Pharmacokinetic; Phase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CELECOXIB; DNA TOPOISOMERASE; IRINOTECAN; MITOMYCIN C; TUMOR MARKER;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER TOXICITY; MALE; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASMS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63949087537     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0826-3     Document Type: Article

References (32)

1. YH Hsiang LF Liu 1988 Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin Cancer Res 48 1722 1726
2. RG Shao CX Cao H Zhang 1999 Replication-medated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes EMBO J 18 1397 1406
3. ML Rothenberg 2001 Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond Oncologist 6 66 80
4. Y Xu MA Villalona-Calero 2002 Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann Oncol 13 1841 1851
5. RJ Reid P Benedetti MA Bjornsti 1998 Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs Bioshio Biophys Acta 1400 289 300
6. F Kanzawa Y Sugimoto K Minato 1990 Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance Cancer Res 50 5919 5924
7. Y Kano K Suzuki M Akutsu 1992 Effects of CPT-11 in combination with other anti-cancer agents in culture Int J Cancer 50 604 610
8. C Gobert L Bracco F Rossi 1996 Modulation of DNA topoisomerase I activity by p53 Biochemistry 35 5778 5786
9. JC Cusack R Liu AS Baldwin 2000 Inducible chemoresistance to 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation Cancer Res 60 2323 2330
10. AS Baldwin 2001 Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB J Clin Invest 107 241 246
11. C Wang JC Cusack R Liu AS Baldwin 1999 Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB Nat Med 5 412 417
12. Y Yamamoto MJ Yin KM Lin 1999 Sulindac inhibits activation of the NF-κB pathway J Biol Chem 274 27307 27314
13. M Yin T Yamamoto RB Gaynor 1998 The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-beta Nature 396 77 80
14. Knuth DW (1999) Bioanalytical method validation: determination of irinotecan (CPT-11) and its SN-38 and APC metabolites in human plasma by isocratic HPLC-FL with protein precipitation and emission wavelength switching (AvTech Laboratories, Inc). Pharmacia & Upjohn Study Report a0032518, 12 Feb 1999
15. Knuth DW (1999) Bioanalytical method validation: Determination of the SN-38 glucuronide metabolite of irinotecan (CPT-11) in human plasma by isocratic HPLC-FL following hydrolysis (AvTech Laboratories, Inc). Pharmacia & Upjohn Study Report a0032541, 25 Feb 1999
16. Method Validation Report Addendum No 7: Evaluation of the Specificity of the HPLC-FL Method for the Determination of CPT-11, SN-38 and APC in Human Plasma for the Coadministered Medication Celecoxib (SC-58635, Celebrex®) and SC-62807 and SC-60613 (2 metabolites of celecoxib). Smart Number CPTAIV-0020-VR1-AD7, 5 March 2003
17. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
18. Dorr RT, Von Hoff DD (eds) (1994) Cancer chemotherapy handbook. Norwalk, Appleton & Lange, p2
19. DR Beidler YC Cheng 1995 Camptothecin induction of a time and concentration dependent decrease of topoisomerase I and its implication into camptothecin activity Mol Pharmacol 47 907 914
20. ML Rothenberg NJ Meropol EA Poplin 2001 Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 18 3801 3807
21. CS Fuchs MR Moore G Harker 2003 Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 21 807 814
22. E Cadenas 1995 Antioxidant and prooxidant functions of DT-diaphorase in quinine metabolism Biochem Pharm 49 127 130
23. J Kolesar M Villalona-Calero G Eckhardt 1995 Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer J Natl Caner Inst 87 13 1022 1024
24. JM Nabholtz HJ Senn WR Bezwoda 1999 Prospective randomized trial of docetaxel versus MMC plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group J Clin Oncol 17 5 1413 1424
25. RS Walters D Frye Buzdar Au 1992 A randomized trial of two dosage schedules of MMC C in advanced breast carcinoma Cancer 69 2 476 481
26. Y Shimizu S Umezawa K Hasumi 1998 A phase II study of combined CPT-11 and mitomycin C in platinum refractory clear cell and mucinous ovarian carcinoma Ann Acad Med Singapore 27 5 650 656
27. MS Braun SD Richman JW Adlard 2006 Association of topoisomerase-1 (Topo1) with the efficacy of chemotherapy in a randomized trial for advanced colorectal cancer patients (FOCUS) J Clin Oncol 24 18S 10009
28. Kohne F, de Greve J, Bokemeyer I et al (2005) Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/1 celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015, ASCO 2005 GI Cancers Symposium, Abstract 3525
29. El-Rayes BF, Zalupski MM, Shields AF et al (2005) A phase II trial of celecoxib, irinotecan and capecitabine in metastatic colorectal cancer. ASCO GI Cancers Symposium 2005, Abstract 3677
30. Lee F, Roach G, Parasher G et al (2005) Irinotecan, capecitabine and celecoxib (ICC) is an effective palliative regimen for unreectable/metastatic cholangiocarcinoma. ASCO GI Cancers Symposium, Abstract 14830
31. OC Trifan WF Durham VS Salazar 2002 Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11 Cancer Res 62 20 5778 5784
32. CS Fuchs J Marshall EP Mitchell 2007 Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations ± celecoxib in mCRC: clinical data cut-off September 1, 2006 J Clin Oncol 25 18S 4027